These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 12011927)
1. Low frequency of side effects following an incidental 25 times concentrated dose of yellow fever vaccine. Rabello A; Orsini M; Disch J; Marcial T; Leal Md Mda L; Freire Md Mda S; Yamamura AM; Viana A Rev Soc Bras Med Trop; 2002; 35(2):177-80. PubMed ID: 12011927 [TBL] [Abstract][Full Text] [Related]
2. The effects of yellow fever immunization (17DD) inadvertently used in early pregnancy during a mass campaign in Brazil. Suzano CE; Amaral E; Sato HK; Papaiordanou PM; Vaccine; 2006 Feb; 24(9):1421-6. PubMed ID: 16236402 [TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of typhoid fever and yellow fever vaccines when administered concomitantly with quadrivalent meningococcal ACWY glycoconjugate vaccine in healthy adults. Alberer M; Burchard G; Jelinek T; Reisinger E; Beran J; Hlavata LC; Forleo-Neto E; Dagnew AF; Arora AK J Travel Med; 2015; 22(1):48-56. PubMed ID: 25308927 [TBL] [Abstract][Full Text] [Related]
4. [Efficacy and safety of vaccination against yellow fever of persons traveling to endemic areas]. Dabrowska MM; Flisiak R Przegl Epidemiol; 2010; 64(2):319-22. PubMed ID: 20731245 [TBL] [Abstract][Full Text] [Related]
5. Safety profile of fractional dosing of the 17DD Yellow Fever Vaccine among males and females: Experience of a community-based pharmacovigilance in Kinshasa, DR Congo. Nzolo D; Engo Biongo A; Kuemmerle A; Lusakibanza M; Lula Y; Nsengi N; Nsibu Ndosimao C; Tona Lutete G; Van Geertruyden JP Vaccine; 2018 Oct; 36(41):6170-6182. PubMed ID: 30190119 [TBL] [Abstract][Full Text] [Related]
6. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Guirakhoo F; Kitchener S; Morrison D; Forrat R; McCarthy K; Nichols R; Yoksan S; Duan X; Ermak TH; Kanesa-Thasan N; Bedford P; Lang J; Quentin-Millet MJ; Monath TP Hum Vaccin; 2006; 2(2):60-7. PubMed ID: 17012873 [TBL] [Abstract][Full Text] [Related]
7. Adverse events following yellow fever preventive vaccination campaigns in eight African countries from 2007 to 2010. Breugelmans JG; Lewis RF; Agbenu E; Veit O; Jackson D; Domingo C; Böthe M; Perea W; Niedrig M; Gessner BD; Yactayo S; Vaccine; 2013 Apr; 31(14):1819-29. PubMed ID: 23395587 [TBL] [Abstract][Full Text] [Related]
8. Yellow Fever Vaccine Booster Doses: Recommendations of the Advisory Committee on Immunization Practices, 2015. Staples JE; Bocchini JA; Rubin L; Fischer M; MMWR Morb Mortal Wkly Rep; 2015 Jun; 64(23):647-50. PubMed ID: 26086636 [TBL] [Abstract][Full Text] [Related]
9. Adverse events following yellow fever immunization: Report and analysis of 67 neurological cases in Brazil. Martins Rde M; Pavão AL; de Oliveira PM; dos Santos PR; Carvalho SM; Mohrdieck R; Fernandes AR; Sato HK; de Figueiredo PM; von Doellinger Vdos R; Leal Mda L; Homma A; Maia Mde L Vaccine; 2014 Nov; 32(49):6676-82. PubMed ID: 24837504 [TBL] [Abstract][Full Text] [Related]
10. Yellow fever vaccine-associated viscerotropic disease and death in Spain. Doblas A; Domingo C; Bae HG; Bohórquez CL; de Ory F; Niedrig M; Mora D; Carrasco FJ; Tenorio A J Clin Virol; 2006 Jun; 36(2):156-8. PubMed ID: 16597510 [TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and Safety of Yellow Fever Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients After Withdrawal of Immunosuppressive Therapy. Sicre de Fontbrune F; Arnaud C; Cheminant M; Boulay A; Konopacki J; Lapusan S; Robin C; Bernaudin F; Suarez F; Simon F; Socié G; Colin de Verdière N; Consigny PH J Infect Dis; 2018 Jan; 217(3):494-497. PubMed ID: 29087520 [TBL] [Abstract][Full Text] [Related]
12. Neurological adverse events temporally associated to mass vaccination against yellow fever in Juiz de Fora, Brazil, 1999-2005. Fernandes GC; Camacho LA; Sá Carvalho M; Batista M; de Almeida SM Vaccine; 2007 Apr; 25(16):3124-8. PubMed ID: 17316927 [TBL] [Abstract][Full Text] [Related]
13. Yellow fever vaccination: how much is enough? Massad E; Coutinho FA; Burattini MN; Lopez LF; Struchiner CJ Vaccine; 2005 Jun; 23(30):3908-14. PubMed ID: 15917112 [TBL] [Abstract][Full Text] [Related]
14. Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: systematic review. Thomas RE; Lorenzetti DL; Spragins W; Jackson D; Williamson T Vaccine; 2011 Jun; 29(28):4544-55. PubMed ID: 21549787 [TBL] [Abstract][Full Text] [Related]
15. Suspected YF-AND after yellow fever vaccination in Finland. Jääskeläinen AJ; Huhtamo E; Kivioja R; Domingo C; Vene S; Kallio-Kokko H; Niedrig M; Tienari PJ; Vapalahti O J Clin Virol; 2014 Nov; 61(3):444-7. PubMed ID: 25223921 [TBL] [Abstract][Full Text] [Related]
16. Reduced intradermal test dose of yellow fever vaccine induces protective immunity in individuals with egg allergy. Roukens AH; Vossen AC; van Dissel JT; Visser LG Vaccine; 2009 Apr; 27(18):2408-9. PubMed ID: 19368780 [TBL] [Abstract][Full Text] [Related]
18. [Antibody responses in Japanese volunteers after immunization with yellow fever vaccine]. Taga K; Imura S; Hayashi A; Kamakura K; Hashimoto S; Takasaki T; Kurane I; Uchida Y Kansenshogaku Zasshi; 2002 Sep; 76(9):738-46. PubMed ID: 12391677 [TBL] [Abstract][Full Text] [Related]
19. Yellow fever vaccination: some thoughts on how much is enough [Vaccine 23 (2005) 3908-3914]. Martins RM; Galler R; Freire MS; Camacho LA; de Lourdes S Maia M; Homma A Vaccine; 2007 Jan; 25(1):10-1. PubMed ID: 16448728 [TBL] [Abstract][Full Text] [Related]